Vacciner mod respiratorisk syncytialvirus

Emil Dariush Lichscheidt; Zitta Barrella Harboe; Thea Kølsen Fischer; Carsten Schade Larsen

doi:10.61409/V12230800

Vacciner mod respiratorisk syncytialvirus

Emil Dariush Lichscheidt, Zitta Barrella Harboe, Thea Kølsen Fischer, Carsten Schade Larsen

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Abstract

Respiratory syncytial virus (RSV is) a common respiratory virus responsible for considerable morbidity and mortality among infants, elderly with comorbidity, and immunocompromised adults. Two vaccines, Abrysvo and Arexvy, have been approved for prevention of severe RSV infection in adults ≥ 60 years of age. In addition, Abrysvo is approved for use during pregnancy to protect infants from RSV-associated lower respiratory tract infection. Currently, there is no national recommendation for the use of the vaccines, but vaccination of elderly at highest risk of severe RSV infection should be considered in a shared clinical decision making.

Bidragets oversatte titel	Vaccines against respiratory syncytial virus
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Læger
Vol/bind	186
Nummer	11
ISSN	0041-5782
DOI	https://doi.org/10.61409/V12230800
Status	Udgivet - mar. 2024

Adgang til dokumentet

10.61409/V12230800Licens: CC BY-NC-ND

Citationsformater

@article{bf678fd8367a495593f1ebaaf7465689,

title = "Vacciner mod respiratorisk syncytialvirus",

abstract = "Respiratory syncytial virus (RSV is) a common respiratory virus responsible for considerable morbidity and mortality among infants, elderly with comorbidity, and immunocompromised adults. Two vaccines, Abrysvo and Arexvy, have been approved for prevention of severe RSV infection in adults ≥ 60 years of age. In addition, Abrysvo is approved for use during pregnancy to protect infants from RSV-associated lower respiratory tract infection. Currently, there is no national recommendation for the use of the vaccines, but vaccination of elderly at highest risk of severe RSV infection should be considered in a shared clinical decision making.",

author = "Lichscheidt, {Emil Dariush} and Harboe, {Zitta Barrella} and Fischer, {Thea K{\o}lsen} and Larsen, {Carsten Schade}",

note = "Publisher Copyright: Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = mar,

doi = "10.61409/V12230800",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "11",

}

TY - JOUR

T1 - Vacciner mod respiratorisk syncytialvirus

AU - Lichscheidt, Emil Dariush

AU - Harboe, Zitta Barrella

AU - Fischer, Thea Kølsen

AU - Larsen, Carsten Schade

N1 - Publisher Copyright: Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/3

Y1 - 2024/3

N2 - Respiratory syncytial virus (RSV is) a common respiratory virus responsible for considerable morbidity and mortality among infants, elderly with comorbidity, and immunocompromised adults. Two vaccines, Abrysvo and Arexvy, have been approved for prevention of severe RSV infection in adults ≥ 60 years of age. In addition, Abrysvo is approved for use during pregnancy to protect infants from RSV-associated lower respiratory tract infection. Currently, there is no national recommendation for the use of the vaccines, but vaccination of elderly at highest risk of severe RSV infection should be considered in a shared clinical decision making.

AB - Respiratory syncytial virus (RSV is) a common respiratory virus responsible for considerable morbidity and mortality among infants, elderly with comorbidity, and immunocompromised adults. Two vaccines, Abrysvo and Arexvy, have been approved for prevention of severe RSV infection in adults ≥ 60 years of age. In addition, Abrysvo is approved for use during pregnancy to protect infants from RSV-associated lower respiratory tract infection. Currently, there is no national recommendation for the use of the vaccines, but vaccination of elderly at highest risk of severe RSV infection should be considered in a shared clinical decision making.

U2 - 10.61409/V12230800

DO - 10.61409/V12230800

M3 - Tidsskriftartikel

C2 - 38533866

AN - SCOPUS:85189259477

SN - 0041-5782

VL - 186

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 11

ER -

Vacciner mod respiratorisk syncytialvirus

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater